Business Wire

CA-TIGO

Share
Tigo Energy Delivers Scalable Insights on EI Platform for High-Growth, Multi-Site Solar Installers

Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today unveiled a new set of powerful and customizable features of the Tigo Energy Intelligence (EI) Platform. With a newly retooled, upgraded, and tiered approach to delivering the right solar monitoring and insights, even small and mid-sized installation companies can manage their growing solar customer portfolios sustainably. These platform enhancements come online as the U.S. installed base of solar surpasses the 5 million solar installations threshold and the industry considers how it will manage the O&M work as those numbers double by 2030 and triple by 2034.

The Tigo EI Platform now offers upgrade options that deliver even more of the right information at the right time via a user-friendly interface to installers, asset managers, and down to the individual system owner. Most notably for rapidly scaling installers, EPCs, and O&M providers, the new EI Professional package provides a centralized view of critical health and performance data of all systems under management. Beyond a scalable monitoring experience and a simple, flat-price model, the EI Professional package includes:

  • one-click enrollment for company-wide, unlimited-seat subscription access covering all systems under management,
  • a portfolio-wide dashboard with a prioritized view into critical data, such as health status, production, performance, equipment status, location data, and commissioning time tracking, and
  • time-saving features including advanced tagging, grouping, and site filtering for improved management, maintenance, optimization, and trend analysis.

Solar installers use the Tigo EI Platform to gain improved insights into installation status, decrease O&M costs, and monitor energy generation and system performance. The standard system-by-system monitoring view, now named EI Basic, remains free of charge, and includes module-level resolution and insight into third-party hardware. More advanced monitoring and analytics tools, historical data, and minute-level monitoring resolution, among others, are available via a simple, in-platform upgrade to EI Premium.

“As we watch the number, size, and complexity of the residential and commercial systems we deploy increase, we found that the only way to scale was with a comprehensive way to monitor, diagnose, and optimize those systems,” said Garrett Brandt, owner at Radius Energy. “When you consider the cost of even a single truck roll or the opportunity cost of a one-week delay in getting an invoice out post-commissioning, a paid subscription to avoid either makes sense right away. The features now available via the Tigo EI Platform don’t just add value in terms of savings but represent new opportunities for us on the installer side.”

Installer training materials for the EI Platform are now available in the Tigo Academy. Tigo Academy offers new and existing customers and installers an efficient way to learn about Tigo software through hands-on demonstrations and tutorials on how to leverage Tigo software for optimal system performance and customer satisfaction.

“To stay competitive, installers have to become more agile while providing more post-installation services, which is why Tigo has developed increasingly sophisticated options in the EI Platform that deliver the right management tools to the variety of customers we serve,” said Archie Roboostoff, vice president of software, at Tigo Energy. “Software plays an increasingly important role in ensuring that solar deployments reach peak performance while continuously analyzing trends to see where improvements can be made. The EI Platform is designed to identify system issues before production is impacted. System owners expect quality and reliability, and the EI Platform helps to deliver both.”

To learn more about the Tigo EI Platform, including the standard capabilities of EI Basic and the features and subscription pricing for EI Premium and EI Professional, please visit the EI features page at https://www.tigoenergy.com/ei/pricing. Tigo installers are also invited to take advantage of promotional trial access to EI Professional for the month of July, which is available via web browser on the Tigo EI Platform: https://ei.tigoenergy.com/

About Tigo Energy

Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709862359/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye